All In Biotech

NDA 022257 · Cheplapharm

Valcyte

Valganciclovir Hydrochloride · Oral

Priority review

Last checked: Nov 20, 2026Latest source record: Dec 23, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Aug 28, 2009

Approved uses

3

Original approval plus efficacy supplements

Registered trials

120

36 Phase 3, 19 recruiting

FAERS reports

19,081

17,710 serious, 3,264 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS Hematologic Toxicity: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow failure including aplastic anemia have been reported in patients treated with VALCYTE [see Warnings and Precautions (5.1) ]. Impairment of Fertility: Based on animal data and limited human data, VALCYTE may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females [see Warnings and Precautions (5.3) ]. Fetal Toxicity: Based on animal data, VALCYTE has the potential to cause birth defects in humans [see Warnings and Precautions (5.4) ]. Mutagenesis and Carcinogenesis: Based on animal data, VALCYTE has the potential to cause cancers in humans [see Warnings and Precautions (5.5) ]. WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF...

What it is approved for

From the label in effect Dec 8, 2025.

VALCYTE is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. Pediatric Patients ( 1.2 ) Prevention of CMV disease in kidney and heart transplant patients at high risk. 1.1 Adult Patients Treatment of Cytomegalovirus (CMV) Retinitis: VALCYTE is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) [see Clinical Studies (14.1) ] . Prevention of CMV Disease: VALCYTE is indicated for the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]) [see Clinical Studies (14.1) ] . 1.2 Pediatric Patients Prevention of CMV Disease: VALCYTE is indicated for the prevention of CMV disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk [see Clinical Studies (14.2) ] .

Mechanism: Valganciclovir is an antiviral drug with activity against CMV [see Microbiology (12.4) ] . Mechanism of Action: Valganciclovir is an L-valyl ester (prodrug) of ganciclovir that exists as a mixture of two diastereomers. After oral administration, both diastereomers are rapidly converted to ganciclovir by intestinal and hepatic esterases. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, which inhibits replication of human CMV in cell culture and in vivo. In CMV-infected cells, ganciclovir is initially phosphorylated to ganciclovir monophosphate by the viral protein kinase, pUL97....

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • VALCYTE · VALGANCICLOVIR HYDROCHLORIDE 50MG/ML · FOR SOLUTION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Valganciclovir" as an intervention, any sponsor and status, largest first.

All 120 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use3,071
  • cytomegalovirus infection1,840
  • drug ineffective1,540
  • neutropenia1,189
  • pyrexia967
  • leukopenia960
  • diarrhoea952
  • acute kidney injury862
  • cytomegalovirus viraemia770
  • death762
  • pancytopenia717
  • drug resistance683

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200483
2005143
2006102
2007115
2008144
2009159
2010175
2011409
2012518
2013413
2014513
2015555
2016608
20171,078
20181,375
20191,683
20201,823
20211,563
20221,563
20231,673
20241,891
20251,509
2026986

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Valcyte (Valganciclovir HCl)

2024 spending

$85K

Beneficiaries

n/a

12 claims

Per beneficiary

n/a

$73.41 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$85,323

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 204 on PubMed

Sponsor: Cheplapharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.